Review article · 2024 · Open access

Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics

Wutong Zhao, Yongbin Jiang, Xiufen Li, Hai Wang

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 16(6), e2020 · Published 1 November 2024 · DOI 10.1002/wnan.2020

Open PDFView at the publisherCite this paper

In brief

“Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics” is a 2024 review article by Wutong Zhao and 3 co-authors, published in Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. OpenAlex counts 20 citations as of 21 November 2026, which puts it in the top 2% of works published in 2024 by citations. It is open access: the full text is free to read at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology.

Citations
20
Most cited in
2026 (11)
Field-weighted impact
0.67
References
84
Authors
4

Abstract

Targeted protein degradation (TPD) represents an innovative therapeutic strategy that has garnered considerable attention from both academic and industrial sectors due to its promising developmental prospects. Approximately 85% of human proteins are implicated in disease pathogenesis, and the FDA has approved around 400 drugs targeting these disease-related proteins, predominantly enzymes, transcription factors, and non-enzymatic proteins. However, existing therapeutic modalities fail to address certain "high-value" targets, such as c-Myc and Ras. The emergence of proteolysis-targeting chimeras (PROTAC) technology has introduced TPD into a new realm. The capability to target non-druggable sites has expanded the therapeutic horizon of protein-based drugs, although challenges related to bioavailability, safety, and adverse side effects have constrained their clinical progression. Nano-delivery systems and emerging TPD modalities, such as molecular glues, lysosome-targeted chimeras (LYTACs), autophagy system compounds (ATTEC), and antibody PROTAC (AbTACs), have mitigated some of these limitations. This paper reviews the latest advancements in TPD, highlighting their applications and benefits in cancer therapy, and concludes with a forward-looking perspective on the future development of this field.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhao, W., Jiang, Y., Li, X., & Wang, H. (2024). Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 16(6), e2020. https://doi.org/10.1002/wnan.2020

MLA 9

Zhao, Wutong, et al. “Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 16, no. 6, 2024, p. e2020. https://doi.org/10.1002/wnan.2020.

Chicago

Zhao, Wutong, Yongbin Jiang, Xiufen Li, and Hai Wang. 2024. “Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 16 (6): e2020. https://doi.org/10.1002/wnan.2020.

Harvard

Zhao, W. et al. (2024) ‘Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics’, Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 16(6), p. e2020. doi:10.1002/wnan.2020.

IEEE

W. Zhao, Y. Jiang, X. Li, and H. Wang, “Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics,” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 16, no. 6, p. e2020, 2024, doi: 10.1002/wnan.2020.

BibTeX

@article{zhao2024nanotechnology,
  title     = {{Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics}},
  author    = {Zhao, Wutong and Jiang, Yongbin and Li, Xiufen and Wang, Hai},
  journal   = {Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology},
  year      = {2024},
  volume    = {16},
  number    = {6},
  pages     = {e2020},
  doi       = {10.1002/wnan.2020},
  url       = {https://doi.org/10.1002/wnan.2020}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • targeted protein degradation
  • PROTACs
  • cancer therapeutics
  • nanoparticle drug delivery
  • molecular glues
  • lysosome-targeting chimeras
  • c-Myc
  • Ras

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Zhao, W., Jiang, Y., Li, X., & Wang, H. (2024). Nanotechnology‐Enabled Targeted Protein Degradation for Cancer Therapeutics. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 16(6), e2020. https://doi.org/10.1002/wnan.2020

How many times has this paper been cited?

20 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology: sign in and open the PDF from this page.

Who wrote this paper?

Wutong Zhao, Yongbin Jiang, Xiufen Li, Hai Wang.

What is the DOI of this paper?

10.1002/wnan.2020, permanently at https://doi.org/10.1002/wnan.2020. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.